Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of prescription drugs.
US FTC Finds Major Pharmacy Benefit Managers Inflated Drug Prices for $7.3 Billion Gain
UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts -- marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue in excess of the acquisition costs of the drugs,
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain
Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
FTC Release: FTC Releases Second Interim Staff Report on Prescription Drug Middlemen
Report finds PBMs charge significant markups for cancer, HIV, and other critical specialty generic drugs The Federal Trade Commission today published a second interim staff report on the prescription drug middleman industry,
4h
Republican bill seeks to curtail US FTC's merger-busting powers
The U.S. Federal Trade Commission's merger-busting, antitrust enforcement powers are coming under threat as conservatives ...
STAT
8m
Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
ConsumerAffairs
2h
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
17h
FTC set to sue Deere over equipment repair practices, Bloomberg News says
The U.S. Federal Trade Commission has prepared a lawsuit against Deere & Co alleging the company's agricultural equipment ...
23h
Federal Trade Commission accuses Greystar of deceptive practices, hidden fees
The antitrust agency recently created a rule regarding junk fees, but its application to the multifamily sector is unclear.
5d
on MSN
Federal Trade Commission sets closed door meeting for next Thursday
The Federal Trade Commission has scheduled a closed-door meeting for next Thursday as FTC Chair Lina Khan's reign nears an ...
13h
Apartment giant Greystar facing FTC lawsuit over misleading rental fees
The suit accuses the company of falsely advertising rental prices by failing to inform renters of numerous mandatory fees.
20h
on MSN
Will ‘click to cancel’ get canceled? New FTC rule faces legal, political challenges
It takes effect Tuesday but its fate is already in doubt. The new FTC rule faces legal challenges and possible opposition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
United States
FTC
Greystar
PayPal
PBMs
Feedback